

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



RMC-4630

Item No. 38772

CAS Registry No.: 2172652-48-9

Formal Name: 6-[(2-amino-3-chloro-4-pyridinyl)

> thio]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-

methyl-2-pyrazinemethanol

Synonym: SAR442720 MF: C20H27CIN6O2S

FW: 451.0 **Purity:** ≥98% Supplied as: A solid -20°C Storage: Stability: ≥4 years NH_2

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

RMC-4630 is supplied as a solid. A stock solution may be made by dissolving the RMC-4630 in the solvent of choice, which should be purged with an inert gas. RMC-4630 is soluble in organic solvents such as DMSO. RMC-4630 is slightly soluble in acetonitrile.

RMC-4630 is slightly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

RMC-4630 is an allosteric inhibitor of Src homology region 2 domain-containing phosphatase 2 (SHP-2).^{1,2}

References

- 1. Jogalekar, A., Won, W., Koltun, E.S., et al. 2,5-Disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors. Revolution Medicines, Inc. WO2018013597A1 (2018).
- 2. Smith, J.A., Singh, M., Nichols, R.J., et al. Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway. Cancer Res. 80(16 Suppl), 1943 (2020).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/13/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM